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OBJECTIVES: The prevalence of electrocardiographic and echocardiographic abnormalities in chronic
obstructive pulmonary disease according to disease severity has not yet been established. The aim of this
study was to assess the prevalence of electrocardiographic and echocardiographic abnormalities in chronic
obstructive pulmonary disease patients according to disease severity.
METHODS: The study included 25 mild/moderate chronic obstructive pulmonary disease patients and 25 severe/
very severe chronic obstructive pulmonary disease patients. All participants underwent clinical evaluation,
spirometry and electrocardiography/echocardiography.
RESULTS: Electrocardiography and echocardiography showed Q-wave alterations and segmental contractility in
five (10%) patients. The most frequent echocardiographic finding was mild left diastolic dysfunction (88%),
independent of chronic obstructive pulmonary disease stage. The proportion of right ventricular overload
(p,0.05) and blockage of the anterosuperior division of the left bundle branch were higher in patients with
greater obstruction. In an echocardiographic analysis, mild/moderate chronic obstructive pulmonary disease
patients showed more abnormalities in segmental contractility (p,0.05), whereas severe/very severe chronic
obstructive pulmonary disease patients showed a higher prevalence of right ventricular overload (p,0.05),
increased right cardiac chamber (p,0.05) and higher values of E-wave deceleration time (p,0.05). Age, sex,
systemic arterial hypertension, C-reactive protein and disease were included as independent variables in a
multiple linear regression; only disease severity was predictive of the E-wave deceleration time [r2 = 0.26,
p=0.01].
CONCLUSION: Chronic obstructive pulmonary disease patients have a high prevalence of left ventricular
diastolic dysfunction, which is associated with disease severity. Because of this association, it is important to
exclude decompensated heart failure during chronic obstructive pulmonary disease exacerbation.
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& INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is char-
acterized by chronic airflow limitation and a range of
pathological changes in the lungs. In addition, COPD
presents significant extra-pulmonary effects and is asso-
ciated with important comorbidities that may contribute to
the disease severity. Chronic airflow limitation is associated
with an abnormal inflammatory response of the lungs to
noxious particles or gases, particularly cigarette smoke (1). The
main causes of morbidity and mortality among COPD patients
are cardiovascular disease (CVD) and lung cancer (2–4).
CVD is the leading cause of death worldwide (5), and
smoking is the main modifiable risk factor related to CVD
(6,7). Among COPD patients, CVD is responsible for
approximately 50% of all hospitalizations and 20% of all
deaths (8). However, population-based studies have sug-
gested that regardless of smoking status, age or sex, a COPD
diagnosis increases the risk of cardiovascular morbidity and
mortality by approximately two fold (9). In summary,
COPD patients appear to face a greater risk of dying from or
being diagnosed with CVD.
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Anthonisen et al. and Sin et al. have already assessed the
association among COPD, CVD and increased serum con-
centrations of inflammatory markers (2,9). Inflammation is
considered to be one of the systemic manifestations of COPD
and provides an alternative hypothesis to explain the
relationship between airflow limitation and cardiovascular
risk (4,9). However, the prevalence of electrocardiographic
and echocardiographic abnormalities in COPD according to
disease severity has not yet been established. Therefore, the
present study aimed to assess the prevalence of electro-
cardiographic and echocardiographic abnormalities in mild/
moderate and severe/very severe COPD patients.
& METHODS
The participants were informed of the proposed study
procedures and provided written informed consent. All
procedures were approved by the Committee for Research
Ethics of the University Hospital at Botucatu Medical
School.
We used the Fisher and Belle formula (10) to estimate the
sample size. The prevalence of cardiovascular hospitaliza-
tion or mortality in COPD patients is approximately 15%
(11), with a 95% confidence interval (CI) and a 10% sample
error. The result was a sample size of 49 patients.
Sixty-two consecutive COPD patients recruited from the
Pulmonary Outpatient Clinic of the university hospital were
evaluated. Patients aged $ 40 years with $10 pack-year
smoking histories were included. The exclusion criteria
included a primary diagnosis of other respiratory diseases
[e.g., asthma, restrictive disorders (tuberculosis sequelae or
interstitial fibrosis], sleep apnea/hypopnea syndrome or
lung cancer. In addition, a primary diagnosis of unstable
angina, congestive heart failure (New York Heart
Association class III or IV) or other chronic diseases, such
as uncontrolled diabetes mellitus, kidney or liver failure and
cancer, also constituted grounds for exclusion. The patients
were assessed on three different days of the same week by
clinical evaluations, spirometry and electrocardiogram/
echocardiogram tests. The COPD diagnosis was confirmed
according to the guidelines established in the Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
(1,12): a post-bronchodilator FEV1/forced vital capacity
(FVC) ratio ,0.70 and an increase ,15% or 200 mL in
FEV1 after inhalation of a ß2 agonist. COPD severity was
categorized according to the GOLD stages, considering the
FEV1 (% predicted) and arterial blood gas values (1).
Measurements
Spirometry was performed using the KOKO spirometer
(Ferrari KOKO, Louisville, CO 80027, USA) before and 15
minutes after the inhalation of 400 mcg of salbutamol
according to the criteria set by the American Thoracic
Society (13). FEV1 values are expressed in liters and as
percentages of FVC or percentages of reference values (14).
Pulse oximetry (SpO2) was assessed using an Onyx oximeter
(Model 9500 Oximeter, Nonin Medical Inc., Minneapolis, MN,
USA) while the patients were breathing room air. Body weight
and height were measured by anthropometric mechanical
scale (Filizola, mod-MIC2/B-A, Sa˜o Paulo, SP, Brazil). Body
mass index [BMI] was calculated using the following formula:
BMI = weight [kg]/height [m2]]. The BMI/airflow obstruc-
tion/dyspnea/exercise capacity (BODE) index was calculated
using the model described by Celli et al. (15) The BODE scores
were categorized as class 1 (score 0 to 2), class 2 (score 3 to 4),
class 3 (score 5 to 6) and class 4 (score 7 to 10) (15). According
to the Seventh Report of the Joint National Committee on the
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure, systemic hypertension was defined as a
systolic blood pressure. 140 mmHg and/or a diastolic blood
pressure .90 mmHg (16). Fasting peripheral blood was
collected, and the plasma was stored at 280 C˚ until analysis.
CRP was assessed in duplicate by high-sensitivity particle-
enhanced immunonephelometry (CardioPhase, Dade Behring
Marburg GmbH, Deerfield, Illinois, USA) with a lower
detection limit of 0.007 mg/L.
Electrocardiogram (EKG)
EKGs were performed on all of the patients. A
MicromedH device (Micromed Biotechnology LTDA,
Wincardio, Brası´lia, DF, Brazil) was used with 12 simulta-
neous leads (DI, DII, DIII, V1, V2, V3, V4, V5, V6, aVR, aVL
and aVF) and digital filters to eliminate the baseline
fluctuation and interference (Wincardio 5.0.4.12, Firebird
editing software). The diagnosis of EKG alteration was
based on the criteria used in the literature (17). The same
examiner performed all tests.
Echocardiographic analysis
The echocardiograph device was an Envisor C model
(Philips Medical Systems, Andover, Massachusetts, USA)
equipped with a 2.0–4.0 MHz probe capable of capturing
second harmonic, tissue, pulsed, continuous and color
Doppler traces, as well as one- and two-dimensional mode
images. With participants positioned in left lateral decubitus
and monitored using an electrocardiographic lead, the
following echocardiographic cuts were performed: short
parasternal axis to measure ventricles, aorta and left atrium
and apical two, four and five chambers to evaluate cavities
and systolic and diastolic functions of ventricles. All of
the measurements were performed in accordance with
the American Society of Echocardiography/European
Association of Echocardiography (18) recommendations.
An average of three measurements was calculated for each
variable. Two operators assessed all echocardiograms; how-
ever, an individual patient’s echocardiograms were assessed
by the same operator. The intra-observer and inter-observer
variabilities were , 3% and 5%, respectively.
The left ventricular (LV) mass (LVM) was calcu-
lated according to the following formula: LVM =
0.86{1.046[(LVDD+IVSDT+PWDT)3-LVDD3]}+0.6, where
LVDD, IVS and PWDT represent the LV diastolic diameter,
interventricular septum and posterior wall thickness,
respectively. The left ventricular systolic function was
evaluated by measuring the ejection fraction (EF) according
to the Teichholz method. The LV diastolic function was
evaluated by measuring the early (E wave) and late (A
wave) diastolic mitral inflow velocities, their ratio, the E
wave deceleration time (EDT) and the isovolumic relaxation
time (IVRT).
Statistical analyses
The mean ¡ SD or the median interquartile range (25–
75%) was used to present the results according to the data
distribution. The patients were divided into two groups
based on disease severity (COPD I/II and COPD III/IV) (1).
When comparing the two study groups, an unpaired t-test
was used for continuous variables, and the Mann-Whitney
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U-test was used for ordinal variables. The Chi-squared test
or Fisher’s exact test was used to evaluate the qualitative
variables. For multiple linear regressions, non-collinear
clinically relevant variables were selected. The included
categorical variables were sex (female = 0, male = 1), sys-
temic arterial hypertension (absence = 0, presence = 1) and
disease severity (COPD I/II = 0 and COPD III/IV = 1). The
continuous variables were age and CRP. Mild left ventri-
cular diastolic dysfunction was considered when the E/A
ratio was ,1, according to the literature.
All of the data were analyzed using the software
SigmaStat 3.2 (SPSS Inc., Chicago, Illinois, USA). Statistical
significance was defined as p,0.05.
& RESULTS
Of the 62 patients initially evaluated, 12 were excluded
from the final analyses, including 6 because of a primary
diagnosis of another respiratory disease, 1 because of
prostate cancer and 5 who did not complete the study
protocol. Thus, 50 patients were included in the final
analysis of the results. Table 1 shows the characteristics of
all 50 COPD patients and also of the two groups according
to the COPD severity. Age and sex did not differ statistically
between the groups. As expected, the patients with severe/
very severe obstruction showed lower values of spirometric
variables and pulse oximetry and higher values of the
BODE index (Table 1).
In five (10%) patients, the electrocardiographic and
echocardiographs presented alterations of the Q wave and
segmental contractility, respectively. Two patients (8%) had
mild/moderate disease, and three (12%) had severe/very
severe disease. All of these patients had received a previous
diagnosis of coronary artery disease, as documented in their
medical records. The most frequent echocardiographic
finding was mild left diastolic dysfunction, which was
observed in 44 patients independently of their COPD stages.
In addition, left atrium enlargement was diagnosed in 46%
of the patients in our sample.
In the current study, differences between the electro-
cardiographic and echocardiographic findings were veri-
fied. Fifty-two percent of patients showed normal or near-
normal EKGs, whereas only 2% had normal echocardio-
grams. The most common electrocardiographic findings are
shown in Table 2. The proportions of right ventricular
overload (p,0.05) and anterosuperior division block of the
left bundle branch were higher in patients with severe/very
severe COPD relative to mild/moderate COPD patients.
The proportions of the other electrocardiographic findings
were similar between the groups (Table 2).
In the echocardiographic analyses, the mild/moderate
COPD patients presented with more abnormalities in
segmental contractility (p,0.05), whereas the severe/very
severe COPD patients displayed a higher prevalence of
right ventricular overload (p,0.05) and increased right
cardiac chamber (p,0.05). The other morphological vari-
ables did not show any statistically significant differences
between the groups (Table 3).
Table 4 shows the systolic and diastolic function of the
studied patients, as evaluated by Doppler echocardiogra-
phy. Patients with severe/very severe obstruction presented
higher values of E-wave deceleration time (EDT) (p,0.05)
than mild/moderate COPD patients. The other variables
did not differ statistically.
Age, sex, systemic arterial hypertension, C-reactive
protein and disease severity (COPD I/II and COPD III/IV)
were included as independent variables in the multiple
linear regression to identify the factors associated with EDT.
Only disease severity showed an association with EDT
[r2 = 0.26, p= 0.01] (Table 5).
& DISCUSSION
The main finding of this study was the high prevalence of
mild left diastolic dysfunction in COPD patients, which was
associated with increased disease severity. Only 10% of our
patients displayed segmental left ventricular wall motion
abnormalities, whereas, as expected, electro- and echocar-
diographic signs of enlargement of the right chambers were
more pronounced in severe/very severe COPD patients.
Ventilation/perfusion mismatch resulting from progres-
sive airflow limitation and emphysema is the key driver of
hypoxia in COPD patients. Hypoxia is associated with
COPD severity and leads to pulmonary vasoconstriction
and right cardiac chamber enlargement, also known as cor
pulmonale. Thus, cor pulmonale is associated with COPD
severity. Schena et al. evaluated patients with cor pulmonale
and pulmonary arterial hypertension secondary to COPD
and found increases in the right ventricular systolic and
diastolic diameters, without left ventricular alteration (19).
However, associations were not observed between echocar-Table 1 - Demographic and spirometric variables of 50
COPD patients according to the GOLD classification.
Variables Total Group (n=50) COPD I/II (n=25) COPD III/IV (n=25)
Sex M/F (N) 31/19 17/8 14/11
Age (years) 67¡9 65¡8 69¡9
FVC (L) 2.5¡0.9 3.2¡0.8 1.9¡0.5*
FVC (%) 81.3¡24.6 98.4¡19.4 64.3¡16.2*
FEV1 (L) 1.3 (0.8–1.7) 1.7 (1.4–2.2) 0.8 (0.6–1.0)*
FEV1 (%) 56.8¡23.6 73.2¡15.6 40.4¡18.4*
SpO2 (%) 93.0¡4.2 94.8¡2.4 91.3¡4.9*
BODE index 2.9¡4.2 1.5¡1.3 4.3¡1.6*
Data are reported as the means ¡ SD or as median interquartile range
(25–75%). M/F =male/female; FVC= forced vital capacity (% of predicted);
FEV1 = forced expiratory volume in the first second (% of predicted);
SpO2=pulse oximetry; BODE index: Body mass index, Obstruction,
Dyspnea, Exercise. GOLD: Global Initiative for Chronic Obstructive Lung
Disease; COPD I/II: mild/moderate; COPD III/IV: severe/very severe.
*p,0.05, COPD I/II compared to COPD III/IV (unpaired t-test or Mann-
Whitney U-test and Chi-squared test).
Table 2 - Electrocardiographic study of the 50 patients
according to COPD severity.
Variables
COPD I/II
(n = 25)
COPD III/IV
(n= 25)
Normal electrocardiogram (%) 26 (52) 26 (52)
Left ventricular hypertrophy (%) 4 (8) 2 (4)
Right ventricular hypertrophy (%) 0 (0) 4 (8)*
Left atrium enlargement (%) 4 (8) 2 (4)
Right atrium enlargement (%) 0 (0) 2 (4)
Q waves (%) 2 (4) 2 (4)
Right bundle branch block (%) 2 (4) 0 (0)
Block of the anterosuperior division
of the left bundle branch (%)
0 (0) 6 (12)*
Sinus tachycardia (%) 0 (0) 2 (4)
COPD I/II: mild/moderate; COPD III/IV: severe/very severe. *p,0.05, COPD I/
II compared to COPD III/IV (Chi-squared test or Fisher’s exact test).
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diographic variables and functional respiratory parameters
(19). In the present study, as expected, the prevalence of
right ventricular hypertrophy and right cardiac chamber
enlargement was higher in patients with severe/very severe
COPD than in those with mild/moderate obstructions.
Although cor pulmonale is a well-known echocardio-
graphic alteration in COPD patients, few studies have
evaluated left ventricular diastolic function in the context of
this disease (20–23). In agreement with our results,
Boussuges et al. found a high prevalence of left ventricular
diastolic dysfunction in COPD patients relative to control
subjects (76% vs. 35%) (20). Although the frequency of
diastolic dysfunction was not as high as in our study (88%),
Rutten et al. and Funk et al. also reported a prevalence
.50%. (21,22). In addition, a recent study showed evidence
of diastolic dysfunction in 47.5% (24) of COPD patients.
However, Freixa et al. found a lower frequency of this
echocardiographic alteration (12%) in COPD patients in
their first hospital admission (25).
Left diastolic dysfunction can be asymptomatic or asso-
ciated with classical heart failure symptoms (diastolic heart
failure). The incidence of diastolic heart failure increases with
age and is more common in older women. Hypertension and
cardiac ischemia are the most common causes of diastolic
heart failure. Other risk factors are obesity and diabetes
mellitus (25). Note that 40% of our patients had systemic
arterial hypertension, whereas 10% had received a previous
diagnosis of ischemic heart disease. In the current study, the
prevalence of ischemic heart disease was lower than that in
previous studies (26,27). Brekke et al. observed that 27.7% of
patients who were hospitalized because of COPD exacerba-
tion showed electrocardiographic signs of myocardial
infarction; 30% of these patients had no previous diagnosis
(27). The higher prevalence of ischemia in these studies may
be have resulted from differences in study design, sample
characteristics and methods used for CVD diagnosis. For
example, in a study by Brekke et al., an electrocardiographic
score was used, which was contrary to Thurnheer et al., who
employed coronarography (27,26). In the present study, the
prevalence of ischemic changes may have been under-
estimated because no additional specific investigation,
beyond electrocardiography and echocardiography, was
performed on patients with no previous diagnoses of
ischemic heart disease.
Recent studies have revealed that diastolic heart failure is
associated with high morbidity and mortality. Patients with
diastolic heart failure have mortality rates of 29% one year
after the diagnosis and 65% after five years (28). Abusaid
et al. evaluated patients who were hospitalized for exacer-
bation of COPD associated with diastolic dysfunction, and
showed that left diastolic dysfunction increased the risk of
hospitalization for exacerbation (29). These data reinforce
the importance of left ventricular diastolic evaluation in
COPD patients.
Note that EDT was increased in patients with severe/very
severe obstruction relative to those with mild or moderate
obstruction. Although nearly all of the patients presented
with mild diastolic dysfunction, the higher EDT values in
severe/very severe COPD suggest that disease severity was
associated with decreased diastolic function. Disease sever-
ity predicts EDT even after adjusting for age, sex, systemic
arterial hypertension and CRP. One explanation for this
association between disease severity and diastolic function
could be systemic inflammation. Inflammation is considered
to be one of the systemic manifestations of COPD and
provides an alternative hypothesis for explaining the
relationship between airflow limitation and atherosclerotic
plaque formation, which are two factors that are also
associated with myocardial ischemia and left ventricular
diastolic dysfunction. Furthermore, the presence of cor
pulmonale secondary to pulmonary hypertension can lead
to interventricular septum deviation toward the left
ventricle, which alters left ventricular geometry and delays
filling (31). This mechanism could also explain why disease
severity was associated with worse diastolic function. In
addition, because of the association between left ventricular
diastolic dysfunction and COPD severity, it is also impor-
tant to exclude decompensated heart failure during COPD
exacerbation.
We should consider the major limitations of the present
work, e.g., its small sample size and the recruitment of all
patients from a single medical center. In addition, tissue
Doppler imaging was not performed for evaluation of
diastolic function. Further studies are needed to elucidate
Table 3 - Morphological echocardiographic evaluation of
the 50 patients according to COPD severity.
Variables COPD I/II (n=25) COPD III/IV (n=25)
Normal echocardiogram (%) 0 (0) 2 (4)
Left atrial enlargement (%) 20 (40) 26 (52)
Dilatation of the aortic root (%) 6 (12) 0 (0)*
Enlargement of the right cardiac
chambers (%)
2 (4) 10 (20)*
Alterations in segment
contractility
4 (8) 0 (0)*
Data are reported as percentages. COPD I/II: mild/moderate; COPD III/IV:
severe/very severe. *p,0.05, COPD I/II compared to COPD III/IV (Chi-
squared test or Fisher’s exact test).
Table 4 - Echocardiographic variables of systolic and
diastolic function of the 50 patients according to COPD
severity.
Variables COPD I/II (n =25) COPD III/IV (n = 25)
EF (Teichholz) 69.0 (67.0–71.2) 70.5 (69.5–73.0)
E/A 0.7 (0.6–0.8) 0.7 (0.6–0.8)
EDT (ms) 234.7¡57.2 283.8¡51.6*
IVRT (MS) 112.0 (112.0–116.0) 112.0 (105.0–112.0)
Data are reported as the means¡SD or as median interquartile range (25–
75%). COPD I/II: mild/moderate; COPD III/IV: severe/very severe. EF:
ejection fraction; E wave: peak velocity of early ventricular filling; A wave:
peak velocity of transmitral flow during atrial contraction; EDT: E-wave
deceleration time; IVRT: isovolumetric relaxation time. *p,0.05, COPD I/II
compared to COPD III/IV (unpaired t-test or Mann-Whitney U-test).
Table 5 - Multiple linear regression to evaluate the
predictors of E-wave deceleration time (r2 = 0.26).
Variables Coefficient Standard Error p-value
Age (years) 20.332 1.068 0.75
Sex 227.332 18.658 0.15
SAH (mmHg) 218.717 19.863 0.35
CRP (mg/L) 20.548 2.350 0.81
Disease severity 51.314 18.672 0.01
SAH: systemic arterial hypertension; CRP: C-reactive protein; disease
severity: COPD I/II (0), COPD III/IV (1).
CLINICS 2013;68(6):772-776 Cardiac function in COPD patients
Caram LM et al.
775
the specific mechanisms associated with COPD severity and
left ventricular diastolic dysfunction.
In conclusion, the electro- and echocardiographic signs of
right chamber enlargement are more pronounced in severe/
very severe COPD patients. In addition, COPD patients
have a high prevalence of left ventricular diastolic dysfunc-
tion, which is associated with disease severity. Thus,
because of this association, it is important to exclude
decompensated heart failure during COPD exacerbation.
Scientific knowledge of the subject
Chronic obstructive pulmonary disease (COPD) patients
have a high prevalence of left ventricular diastolic dysfunc-
tion according to disease severity.
What this study adds to the field
COPD patients have a high prevalence of electrocardio-
graphic and echocardiographic abnormalities regardless of
disease severity.
COPD patients have a high prevalence of left ventri-
cular diastolic dysfunction, which is associated with
disease severity. Because of this association, it is impor-
tant to exclude decompensated heart failure during COPD
exacerbation.
& ACKNOWLEDGMENTS
This study received financial support from the Foundation for the Support
of Research in the State of Sa˜o Paulo (FAPESP), grant no. 2010/10312-1.
Laura Miranda de Oliveira Caram was the recipient of a scholarship grant
from CAPES.
& AUTHOR CONTRIBUTIONS
Caram LM, Minicucci MF and Godoy I conceived the study. Caram LM,
Minicucci MF, Tanni SE and Ferrari R performed the statistical analysis.
Caram LM, Minicucci MF, Tanni SE and Godoy I analyzed the data and
drafted the manuscript. Caram LM, Ferrari R, Naves CR, Coelho LS and
Zanatti SG contributed to the data collection. All of the authors
contributed to the writing of the manuscript, read and approved its final
version.
& REFERENCES
1. GOLD. Global Strategy for the diagnosis, management, and prevention
of chronic obstructive pulmonary disease: GOLD Executive Summary
update 2011. wwwgoldcopdorg.
2. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connet
JE. The effects of a smoking cessation intervention on 14.5-year mortality:
a randomized clinical trial. Ann Intern Med. 2005;142(4):233-9.
3. Sin DD, Wu LL, Man SF. The relationship between reduced lung
function and cardiovascular mortality: a population-based study and a
systematic review of the literature. Chest. 2005;127(6):1952-9.
4. Maclay JD, McAllister DA, Macnee W. Cardiovascular risk in chronic
obstructive pulmonary disease. Respirology. 2007;12(5):634-41, http://
dx.doi.org/10.1111/j.1440-1843.2007.01136.x.
5. WHO. World Health Organization in www.who.int/cardiovascular_
disease/en/acessado em julho de 2012.
6. Howard G, Wagenknecht LE, Burke GL, Diez-Roux A, Evans GW,
McGovern P, et al. Cigarette smoking and progression of atherosclerosis:
The atherosclerosis risk in communities (ARIC) study. JAMA.
1998;279(2):119-24, http://dx.doi.org/10.1001/jama.279.2.119.
7. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect
of potencially modifiable risk factors associated with myocardial
infarction in 52 countries (the INTERHEART study): case-control study.
Lancet. 2004;364(9438):937-52, http://dx.doi.org/10.1016/S0140-6736(04)
17018-9.
8. Sin DD, Man SF. Impact of cancers and cardiovascular disease in chronic
obstructive pulmonary disease.Obstructive, occupational and environ-
mental diseases. Curr Opin Pulm Med. 2008;14(2):115-21, http://dx.doi.
org/10.1097/MCP.0b013e3282f45ffb.
9. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary
disease at increased risk of cardiovascular diseases? The potential role
of systemic inflammation in chronic obstructive pulmonary disease.
Circulation. 2003;107(11):1514-9.
10. Fisher LD, Belle GV. Biostatistics: a methodology for health science. New
York: John Wiley; 1993.
11. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and
outcomes of diabetes, hypertension and cardiovascular disease in
COPD. Eur Respir J. 2008;32(4):962-9, http://dx.doi.org/10.1183/
09031936.00012408.
12. Fabbri LM, Luppi F, Beghe B, Rabe KF. Update in chronic obstructive
pulmonary disease 2005. Am J Respir Crit Care Med. 2006;173(10):1056-
65, http://dx.doi.org/10.1164/rccm.2603005.
13. American Thoracic Society Statement. Standardization of spirometry–
1987 update. Statement of the American Thoracic Society. Am Rev Respir
Dis. 1987;136(5):1285-98.
14. Pereira CAC, Barreto SP, Simo˜es JG, Pereira FWL, Gerstler JG, Nakatani
J. Valores de refereˆncia para a espirometria em uma amostra da
populac¸a˜o brasileira adulta. J Bras Pneumol. 1992;18(1):10-22.
15. Celli BR, Cote CG, Marin JM, Casanova C. The body-mass index, airflow
obstruction, dyspnea, and exercise capacity index in chronic obstructive
pulmonary disease. N Engl J Med. 2004;350(10):1005-12.
16. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL
Jr, et al. Seventh report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure.
Hypertension. 2003;42(6):1206-52, http://dx.doi.org/10.1161/01.HYP.
0000107251.49515.c2.
17. Mivris DM, Goldberger AL. Electrocardiography. In: Libby P, Bonow
RO, Mann DL, Zipes DP, eds. Braunwald’s Heart Disease. A test book of
cardiovascular medicine. Philadelphia, PA, USA: Saunders Elsevier.
2008;149-93.
18. Lang RM Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA,
et al. Recommendations for chamber quantification. Eur J Ecocardiogr.
2006;7(2):79-108.
19. Schena M, Clini E, Errera D, Quadri A. Echo-Doppler evaluation of
left ventricular impairment in chronic corpulmonale. Chest.
1996;109(6):1446-51, http://dx.doi.org/10.1378/chest.109.6.1446.
20. Boussuges A, Pinet C, Molenat F, Burnet H, Ambrosi P, Badier M, et al.
Left atrial and ventricular filling in chronic obstructive pulmonary
disease. An echocardiographic and Doppler study. Am J Respir Crit Care
Med. 2000;162(2 Pt1):670-5.
21. Rutten FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH, Lammers JW,
et al. Unrecognized heart failure in elderly patients with stable chronic
obstructive pulmonary disease. Eur Heart J. 2005;26(18):1887-94, http://
dx.doi.org/10.1093/eurheartj/ehi291.
22. Funk CG, Lang I, Schenk P, Valipour A, Hartl S, Burghuber OC. Left
ventricular diastolic dysfunction in patients with COPD in the presence
and absence of elevated pulmonary arterial pressure. Chest.
2008;133(6):1354-9, http://dx.doi.org/10.1378/chest.07-2685.
23. Sabit R, Bolton CE, Fraser AG, Edwards JM, Edwards PH, Ionescu AA,
et al. Sub-clinical left and right ventricular dysfunction in patients with
COPD. Respir Med. 2010;104(8):1171-8, http://dx.doi.org/10.1016/j.
rmed.2010.01.020.
24. Gupta NK, Agrawal RK, Srivastav AB, Ved ML, Echocardiographic
evaluation of heart in chronic obstructive pulmonary disease patient and
its co-relation with the severity of disease. Lung India. 2011;28(2):105-9.
25. Freixa X, Portillo K, Pare´ C, Garcia-Aymerich J, Gomez FP, Benet M, et al.
Echocardiographic abnormalities in patients with COPD at their first
hospital admission. Eur Respir J. 2012; Sep 27 [Epub ahead of print].
26. Kazik A, Wilczek K, Polonski L. Management of diastolic heart failure.
Cardiol J. 2010;17(7):558-65.
27. Thurnheer R, Muntwyler J, Stammberger U, Bloch KE, Zollinger A,
Weder W, et al. Coronary artery disease in patients undergoing lung
volume reduction surgery for emphysema. Chest. 1997;112(1):122-8,
http://dx.doi.org/10.1378/chest.112.1.122.
28. Brekke PH, Omland T, Smith P, Soyseth V. Underdiagnosis of
myocardial infarction in COPD - Cardiac infarction injury score
(CIIS) in patients hospitalised for COPD exacerbation. Respir Med.
2008;102(9):1243-7, http://dx.doi.org/10.1016/j.rmed.2008.04.010.
29. Fontes-Carvalho R, Leite Moreira A. Heart failure with preserved
ejection fraction: fighting misconceptions for a new approach. Arq Bras
Cardiol. 2011;96(6):504-14, http://dx.doi.org/10.1590/S0066-782X20110
00600012.
30. Abusaid GH, Barbagelata A, Tuero E, Mahmood A, Sharma G. Diastolic
dysfunction and COPD exacerbation. Postgrad Med. 2009;121(4):76-81,
http://dx.doi.org/10.3810/pgm.2009.07.2033.
31. Minai AO, Chaouat A, Adnot S. Pulmonary Hypertension in COPD:
Epidemiology, Significance, and Management: Pulmonary Vascular
Disease: The Global Perspective. Chest. 2010;137(6 Suppl):39S-51S,
http://dx.doi.org/10.1378/chest.10-0087.
Cardiac function in COPD patients
Caram LM et al.
CLINICS 2013;68(6):772-776
776
